Tbio | Fc receptor-like protein 3 |
Promotes TLR9-induced B-cell proliferation, activation and survival but inhibits antibody production and suppresses plasma cell differentiation. Enhances activation of NF-kappa-B and MAPK signaling pathways in TLR9 stimulated B-cells (PubMed:23857366). Has inhibitory potentional on B-cell receptor (BCR)-mediated signaling, possibly through association with SH2 domain-containing phosphatases. Inhibits cell tyrosine phosphorylation, calcium mobilization and activation-induced cell death induced through BCR signaling (PubMed:19843936). Regulatory T-cells expressing FCRL3 exhibit a memory phenotype, are relatively nonresponsive to antigenic stimulation in presence of IL2 and have reduced capacity to suppress the proliferation of effector T-cells (PubMed:20190142, PubMed:19494275).
This gene encodes a member of the immunoglobulin receptor superfamily and is one of several Fc receptor-like glycoproteins clustered on the long arm of chromosome 1. The encoded protein contains immunoreceptor-tyrosine activation motifs and immunoreceptor-tyrosine inhibitory motifs in its cytoplasmic domain and may play a role in regulation of the immune system. Mutations in this gene have been associated with rheumatoid arthritis, autoimmune thyroid disease, and systemic lupus erythematosus. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2016]
This gene encodes a member of the immunoglobulin receptor superfamily and is one of several Fc receptor-like glycoproteins clustered on the long arm of chromosome 1. The encoded protein contains immunoreceptor-tyrosine activation motifs and immunoreceptor-tyrosine inhibitory motifs in its cytoplasmic domain and may play a role in regulation of the immune system. Mutations in this gene have been associated with rheumatoid arthritis, autoimmune thyroid disease, and systemic lupus erythematosus. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2016]
Comments
Disease | Target Count | Z-score | Confidence |
---|---|---|---|
Graves Disease | 11 | 0.0 | 0.0 |
Thyroiditis, Autoimmune | 4 | 0.0 | 0.0 |
Disease | Target Count |
---|---|
Autoimmune thyroiditis | 27 |
Disease | Target Count | P-value |
---|---|---|
psoriasis | 6694 | 1.1e-30 |
osteosarcoma | 7950 | 1.2e-04 |
interstitial cystitis | 2312 | 4.6e-03 |
ulcerative colitis | 1819 | 8.5e-03 |
nasopharyngeal carcinoma | 1058 | 1.9e-02 |
non primary Sjogren syndrome sicca | 891 | 2.4e-02 |
ductal carcinoma in situ | 1745 | 4.3e-02 |
Disease | Target Count | Z-score | Confidence |
---|---|---|---|
Thyrotoxicosis | 38 | 0.0 | 3.0 |
Type 1 diabetes mellitus | 109 | 0.0 | 3.0 |
Disease | Target Count | Z-score | Confidence |
---|---|---|---|
Rheumatoid arthritis | 1191 | 4.263 | 2.1 |
Hypersensitivity reaction type II disease | 253 | 4.233 | 2.1 |
Disease | log2 FC | p |
---|---|---|
ductal carcinoma in situ | 1.300 | 4.3e-02 |
interstitial cystitis | 3.700 | 4.6e-03 |
nasopharyngeal carcinoma | -1.500 | 1.9e-02 |
non primary Sjogren syndrome sicca | -1.400 | 2.4e-02 |
osteosarcoma | -1.343 | 1.2e-04 |
psoriasis | 2.400 | 1.1e-30 |
ulcerative colitis | 1.900 | 8.5e-03 |
MLLWLLLLILTPGREQSGVAPKAVLLLNPPWSTAFKGEKVALICSSISHSLAQGDTYWYHDEKLLKIKHD 1 - 70 KIQITEPGNYQCKTRGSSLSDAVHVEFSPDWLILQALHPVFEGDNVILRCQGKDNKNTHQKVYYKDGKQL 71 - 140 PNSYNLEKITVNSVSRDNSKYHCTAYRKFYILDIEVTSKPLNIQVQELFLHPVLRASSSTPIEGSPMTLT 141 - 210 CETQLSPQRPDVQLQFSLFRDSQTLGLGWSRSPRLQIPAMWTEDSGSYWCEVETVTHSIKKRSLRSQIRV 211 - 280 QRVPVSNVNLEIRPTGGQLIEGENMVLICSVAQGSGTVTFSWHKEGRVRSLGRKTQRSLLAELHVLTVKE 281 - 350 SDAGRYYCAADNVHSPILSTWIRVTVRIPVSHPVLTFRAPRAHTVVGDLLELHCESLRGSPPILYRFYHE 351 - 420 DVTLGNSSAPSGGGASFNLSLTAEHSGNYSCDADNGLGAQHSHGVSLRVTVPVSRPVLTLRAPGAQAVVG 421 - 490 DLLELHCESLRGSFPILYWFYHEDDTLGNISAHSGGGASFNLSLTTEHSGNYSCEADNGLGAQHSKVVTL 491 - 560 NVTGTSRNRTGLTAAGITGLVLSILVLAAAAALLHYARARRKPGGLSATGTSSHSPSECQEPSSSRPSRI 561 - 630 DPQEPTHSKPLAPMELEPMYSNVNPGDSNPIYSQIWSIQHTKENSANCPMMHQEHEELTVLYSELKKTHP 631 - 700 DDSAGEASSRGRAHEEDDEENYENVPRVLLASDH 701 - 734 //